Flag of the European Union EU Clinical Trials Register Help

Clinical trials for pancreatic cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    518 result(s) found for: pancreatic cancer. Displaying page 5 of 26.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-001408-23 Sponsor Protocol Number: ABI-007-PANC-007 Start Date*: 2015-03-05
    Sponsor Name:Celgene Corporation
    Full Title: NAB-PACLITAXEL (ABRAXANE®) PLUS GEMCITABINE IN SUBJECTS WITH LOCALLY ADVANCED PANCREATIC CANCER (LAPC): AN INTERNATIONAL, OPEN-LABEL, MULTI-CENTER, PHASE 2 STUDY (LAPACT)
    Medical condition: Locally advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003759-13 Sponsor Protocol Number: GI1931 Start Date*: 2019-12-20
    Sponsor Name:Department of Oncology, Herlev & Gentofte
    Full Title: Phase 1/2 study in borderline resectable, locally advanced or metastatic pancreatic cancer to assess safety and potential efficacy of dual checkpoint inhibition in combination with gemcitabine and ...
    Medical condition: Locally advanced pancreatic cancer, non-resectable or borderline resectable, or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004102-27 Sponsor Protocol Number: SCI-RP-Pan-P2-001 Start Date*: 2008-02-20
    Sponsor Name:SciClone Pharmaceuticals, Inc.
    Full Title: A Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Unre...
    Medical condition: metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033605 Pancreatic cancer metastatic LLT
    9.1 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Ongoing) NL (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000461-10 Sponsor Protocol Number: ISRCTN43482138 Start Date*: 2006-08-25
    Sponsor Name:The Royal Liverpool University Hospital NHS Trust
    Full Title: A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination gemcitabine and capecitabine therapy with concurrent and sequential chemoimmunotherapy using a tel...
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10033633 Pancreatic neoplasms malignant (excl islet cell and carcinoid) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002074-46 Sponsor Protocol Number: FIONA Start Date*: 2013-08-02
    Sponsor Name:Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli – Fondazione “G.Pascale”
    Full Title: Multicentre, two-stage, phase 2 study of neoadjuvant FOLFIRINOX followed by chemo-IMRT in patients with locally advanced unresectable pancreatic cancer
    Medical condition: Locally advanced unresectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-005022-71 Sponsor Protocol Number: C-II-004 Start Date*: 2008-01-17
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research – EWIV
    Full Title: Prospective randomized Phase II trial with gemcitabine plus sunitinib versus gemcitabine alone in first-line therapy of metastatic or locally advanced pancreatic cancer
    Medical condition: metastatic or locally advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001163-12 Sponsor Protocol Number: 1604 Start Date*: 2016-06-26
    Sponsor Name:Herlev University Hospital, Oncology Dept.
    Full Title: A Single Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Gemcitabine (GEM) and Capecitabine (CAP) with or without T-ChOSTM as adjuvant therapy in patients with surgically rese...
    Medical condition: pt with surgically resected pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001463-23 Sponsor Protocol Number: D12-2 Start Date*: 2013-09-05
    Sponsor Name:GERCOR
    Full Title: Randomized Phase II Study of Weekly ABI-007 plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients with Metastatic Pancreatic Cancer.
    Medical condition: metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004086-24 Sponsor Protocol Number: AIO-PAK-0114 Start Date*: 2015-11-18
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Induction Treatment with nab-Paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and nab-Paclitaxel...
    Medical condition: metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001714-15 Sponsor Protocol Number: Met.Panc.01 Start Date*: 2013-07-23
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie
    Full Title: Phase II trial of capecitabine (Xeloda®) + nab-paclitaxel (Abraxane®) in patients with metastatic pancreatic cancer
    Medical condition: metastatic pancreatic adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005961-36 Sponsor Protocol Number: AEG35156-201 Start Date*: 2008-03-27
    Sponsor Name:Aegera Therapeutics Inc.
    Full Title: A Phase 1-2, Multicenter, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
    Medical condition: Advanced pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003753-26 Sponsor Protocol Number: GS-US-324-0101 Start Date*: 2012-05-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
    Medical condition: Metastatic Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000888-41 Sponsor Protocol Number: MetNET1trial Start Date*: 2014-06-05
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei tumori
    Full Title: Activity and safety of Everolimus in combination with octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, mono...
    Medical condition: advanced/ or not resectable well differnciated pancreatic neuroendocrin tumor
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004309-41 Sponsor Protocol Number: PRODIGE61-FFCD1702 Start Date*: 2018-06-27
    Sponsor Name:Fédération francophone de cancérologie digestive
    Full Title: Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed by two months of gemcitabine+Nab-paclitaxel, in metastatic...
    Medical condition: Metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052747 Adenocarcinoma pancreas PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-005314-12 Sponsor Protocol Number: WX/60-004 Start Date*: 2007-01-05
    Sponsor Name:Wilex AG
    Full Title: A randomised, open label, Phase II Proof of Concept study of WX-671 in combination with gemcitabine vs gemcitabine in patients with locally advanced, non-resectable pancreatic cancer in order to ev...
    Medical condition: Locally advanced, non-resectable pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007633-39 Sponsor Protocol Number: MORAb-009-002 Start Date*: 2008-04-03
    Sponsor Name:Morphotek, Inc.
    Full Title: Estudio fase 2 aleatorizado, controlado con placebo, de doble ciego sobre la eficacia de MORAb-009 en combinación con gemcitabina en pacientes con cáncer de páncreas avanzado
    Medical condition: Español: Cáncer de páncreas avanzado en pacientes con enfermedad no extirpable que no han recibido quimioterapia o radioterapia previa para el cáncer de páncreas. Ingles : Advanced pancreatic can...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004605-29 Sponsor Protocol Number: ML19537 Start Date*: 2006-05-09
    Sponsor Name:ROCHE
    Full Title: A Phase IIIb Study of Tarceva (Erlotinib) in patients with locally advanced, unresectable or metastatic pancreatic cancer
    Medical condition: Locally advanced, unresectable or metastatic pancreatic cancer (adenocarcinoma)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000349-14 Sponsor Protocol Number: CNIS793B12201 Start Date*: 2020-08-13
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, open label, randomized, parallel arm study of NIS793 (with and without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alo...
    Medical condition: Pancreatic ductal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) FR (Temporarily Halted) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) BE (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006819-75 Sponsor Protocol Number: CRAD001C2324 Start Date*: 2007-10-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine t...
    Medical condition: Pancreatic neuroendocrine tumors (also called pancreatic endocrine tumors or islet cell tumors (ICT))
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed) DE (Completed) ES (Completed) FR (Completed) GR (Completed) BE (Completed) GB (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020979-23 Sponsor Protocol Number: PACT-17 Start Date*: 2010-07-21
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Randomized fase II study using chemiotherapy with metformine in patients affected by pancreas metastatic cancer.
    Medical condition: pancreas metastatic tumor
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033632 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 27 19:13:36 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA